Samsung Bioepis has announced the launch of its Imraldi, an adalimumab biosimilar to Humira, in the European Union (EU); the drug will be available immediately on the UK鈥檚 National Health Service (NHS).
This follows the expiry of AbbVie鈥檚 patent for Humira in Europe on 16 October this year.
Imraldi was approved by the European Commission (EC) in August 2017 for the treatment of the 13 auto-immune conditions that Humira is approved for. These include rheumatoid arthritis, axial spondyloarthritis, psoriasis, Crohn鈥檚 disease and uveitis.
In two studies Imraldi demonstrated equivalent pharmacokinetics and efficacy, and comparable safety and immunogenicity with Humira. One of the studies was on healthy volunteers to show pharmacokinetic bioequivalence. The other was a 52 week phase III trial on patients with moderate to severe rheumatoid arthritis in which the endpoint, demonstrating equivalent efficacy to Humira, was met.
Samsung Bioepis is a joint venture between and . The approval means that Biogen鈥檚 portfolio of anti-TNF biosimilars in Europe has increased to three. The others are Benepali, a biosimilar to Enbrel, and Flixabi, a biosimilar to Remicade.
Biogen鈥檚 regional director of UK, Ireland and the Netherlands Dan Cohen said: 鈥淲e are proud to be pioneering innovation in biosimilars to help transform the lives of people in the UK with chronic autoimmune conditions.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalData鈥淲ith the addition of IMRALDI to our anti-TNF biosimilar offering, we are increasing clinician choice and patient access in the UK to affordable treatments across disease areas.鈥�
In April this year, Samsung Bioepis signed a patent agreement with AbbVie over the licensing of its Humira biosimilar in the US.
Under the agreement, AbbVie will grant Samsung Bioepis a non-exclusive license to Humira biosimilars from 30 June 2023, after which Samsung Bioepis will pay royalties to license Humira patents.
The terms of the deal were not disclosed but, according to Reuters, AbbVie said it would make no payments to Samsung Bioepis and all parties agreed to dismiss all pending lawsuits.
AbbVie has signed similar deals over Humira in the US with , Sandoz and Mylan.
